Overview

Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)

Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
6 month study of NUEDEXTA ® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients.
Phase:
Phase 4
Details
Lead Sponsor:
Avanir Pharmaceuticals
Treatments:
Dextromethorphan
Quinidine
Quinidine gluconate